Sanofi Acomplia obesity NDA likely to see action by April
This article was originally published in Pharmaceutical Approvals Monthly
Sanofi-Aventis submitted a complete response to FDA's Feb. 17 "approvable" letter for an obesity indication for Acomplia (rimonabant) on Oct. 26. Class 2 designation for the submission would carry an April 26, 2007, user fee date; Class 1 designation would hold the potential of action by year-end...
You may also be interested in...
Amneal is close to a filed pipeline of three biosimilar products in the US, while furthering ambitions in the complex generics and 505(b)(2) space, management told the virtual J.P. Morgan Healthcare Conference.
Zydus Cadila is to begin testing a three-dose recombinant DNA vaccine candidate in Phase III Indian trials, which might enter late-stage development ahead of Inovio and AnGes. The company promised to provide 100-150 million doses by end of 2021 at the J.P. Morgan Conference, though adherence could be a roadblock.
Sun Pharma’s founder and MD shares with Scrip his views on some key big picture issues, including leveraging pandemic-related regulatory experience for urgently needed products, expectations in the US market, the outlook for M&A, and the potential of e-pharmacies in India.